Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Tirzepatide 2.5mg weekly

"Tirzepatide 2.5 mg/0.5 mL solution for injection vial or pre-filled pen. Each vial/ pre-filled pen contains tirzepatide 2.5 mg in 0.5 mL solution (2.5mg in 0.6mL if Kwikpen)~Tirzepatide will be administered by drawing up into a syringe, then administering by subcutaneous injection weekly by study nurses."

DRUG

Placebo injection (normal saline)

Placebo will be given as 0.5mL normal saline (if comparator against vial or pre-filled pen), or 0.6mL (if comparator against Mounjaro Kwikpen), drawn up into a syringe and administered by subcutaneous injection weekly by study nurses.

Trial Locations (1)

2010

Garvan Institute of Medical Research, Sydney

All Listed Sponsors
lead

Garvan Institute of Medical Research

OTHER